In a recent post on the IVI-sponsored Health Affairs featured blog series, Daniel Blumenthal, Mark Linthicum (IVI Director of Scientific Communications), and Sachin Kamal-Bahl (Member, IVI Strategic Advisory Panel) discuss challenges in establishing outcomes-based pricing agreements for pharmaceuticals and potential strategies for overcoming obstacles. Strategies discussed include focusing on legal and regulatory changes, increased information sharing, and greater investment in infrastructure and human capital.
Read the full article here.
About the Health Affairs/IVI Featured Blog Series: Drugs and Medical Innovation — In partnership with Health Affairs, IVI is proud to sponsor the “Drugs and Medical Innovation” blog series. On an ongoing basis, articles in this series will explore topics such as value-based reimbursement, drug policy and pricing, balancing short-term access against long-term rates of innovation, and other relevant issues. Our goal is to create an open forum for sharing ideas and debating issues in these areas, extending the discussion to a broader audience.